Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms (Q40589267)

21 September 2017

title

Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms (English)

1 reference

21 September 2017

6

Harriet Robinson

1 reference

21 September 2017

Dennis Ellenberger

1

1 reference

21 September 2017

Bin Li

2

1 reference

21 September 2017

James Smith

3

1 reference

21 September 2017

Hong Yi

4

1 reference

21 September 2017

Thomas Folks

5

1 reference

21 September 2017

Salvatore Butera

7

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

21 September 2017

number of pages

13

1 reference

inferred from page(s)

published in

Virology

1 reference

21 September 2017

volume

319

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

118-130

1 reference

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from guinea-bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Virus-cell and cell-cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Active human immunodeficiency virus protease is required for viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Escape of human immunodeficiency virus from immune control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Mutational analysis of two zinc finger motifs in HIV type 1 nucleocapsid proteins: effects on proteolytic processing of Gag precursors and particle formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Distribution of HIV-1 subtypes among HIV-seropositive patients in the interior of Côte d'Ivoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

HIV versus cytotoxic T lymphocytes--the war being lost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Role of Cellular Immunity in Protection against HIV Infection**This article was accepted for publication on 31 October 1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Genetic immunization is a simple method for eliciting an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Direct gene transfer into mouse muscle in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

Simian immunodeficiency virus DNA vaccine trial in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

7 January 2021

inferred from DOI database lookup

Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

7 January 2021

inferred from DOI database lookup

Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.013

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VIROL.2003.10.013

1 reference

21 September 2017

1 reference